title: Nocturnal polyuria with abnormal circadian rhythm of plasma arginine vasopressin in post-stroke patients.
abstract: OBJECTIVE
  Nocturia is a common reason for interrupted sleep in post-stroke patients. These patients often have neurogenic bladder overactivity. However, little is known about the possible contribution of nocturnal polyuria in the patients.
  
  
  METHODS
  We measured the number of nocturia, the circadian plasma arginine vasopressin (AVP) level and urinary excretion in 4 patients with stroke.
  
  
  RESULTS
  All patients had nocturnal urinary frequency (three times in one and twice in 3). All patients were revealed to have nocturnal polyuria, and the ratio of nocturnal urinary output to 24 hour volume ranged from 36% to 63%. Measurement of daily plasma AVP variation showed that all patients lost normal nocturnal rise of the plasma AVP concentration. Two patients were successfully treated with 5 mug of intranasal desmopressin once a night, a potent analogue of AVP, without hypertension particularly in the night, signs of congestive cardiac failure or any electrolyte abnormality such as hyponatremia.
  
  
  CONCLUSIONS
  Our post-stroke patients had nocturnal polyuria with abnormal circadian rhythm of plasma AVP secretion. Desmopressin reduced nocturnal waking in urination. It also ameliorated nocturnal dehydration that might trigger a stroke recurrence in the patients.
authors.affiliation: Department of Neurology, Chiba University, Chiba.
authors.forename: Ryuji
authors.initials: R
authors.lastname: Sakakibara
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Uchiyama
authors.forename: Zhi
authors.initials: Z
authors.lastname: Liu
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Ito
authors.forename: Tomonori
authors.initials: T
authors.lastname: Yamanishi
authors.forename: Takamichi
authors.initials: T
authors.lastname: Hattori
mesh_terms: D000281:Administration, Intranasal; D000368:Aged; D001127:Arginine Vasopressin / Q000031:analogs & derivatives / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002544:Cerebral Infarction / Q000097:blood / Q000150:complications* / Q000175:diagnosis; D002940:Circadian Rhythm / Q000502:physiology*; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D011141:Polyuria / Q000097:blood* / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D012076:Renal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D001743:Urinary Bladder / Q000503:physiopathology
chemical_list: D015415:Biomarkers; D012076:Renal Agents; D001127:Arginine Vasopressin; D003894:Deamino Arginine Vasopressin